Clinical Trials
5 trialsNCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT05137886 2021-12-17
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04514081 2020-08-18
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT04233294 2020-08-14
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT03250962 2019-04-01
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown